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We review the methods and results of Stenting and Aggressive Medical Management for
Preventing Recurrent Stroke (SAMMPRIS) and provide a critical review of its strengths and
limitations. In SAMMPRIS, the aggressive medical treatment arm (AMT arm) did substan-
tially better than the Wingspan Stenting plus aggressive medical management arm (WS+
arm). Complications in the first 30 days post intervention led to the disparity between
treatment arms. A major contribution of SAMMPRIS was the added value that AMT and
lifestyle change may provide, when compared to a precursor trial,Warfarin–Aspirin Sympto-
matic Intracranial Disease (WASID), designed to prevent stroke in persons with high-grade
symptomatic intracranial occlusive disease, however, the results of neither of these two
trials have ever been reproduced. On the other hand, we argue that technical limitations
of the Wingspan stent system (WS System) and lack of an angioplasty only intervention
arm may have led to a premature launch of the trial and early termination of the study.
Future randomized trials with different devices and modified patient selection criteria are
warranted.
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INTRODUCTION
Recently, an important intracranial stenting prevention trial in
patients with symptomatic intracranial atherosclerotic occlusive
disease (sICAD), Stenting and Aggressive Medical Management
for Preventing Recurrent Stroke (SAMMPRIS), was published
(1). SAMMPRIS showed that AMT alone was superior to the
Wingspan system plus aggressive medical therapy (WS+ arm).
The main findings were unexpected by some. The publication
of the results, we believe, has reduced intracranial endovascu-
lar revascularization (IER) therapies leaving those patients with
intracranial atherosclerotic stenosis who have failed medical man-
agement without an alternative treatment strategy despite a high
risk of stroke, minimum 12.2%, in the first year. In this topical
review, we discuss the main results and limitation of SAMMPRIS,
and re-address the question as to whether or not the findings were
really surprising based on prior scientific information. In addition,
we discuss strategies to advance the field of IER.
BRIEF HISTORY OF CAROTID-ARTERY SURGERY AND
ENDOVASCULAR INTERVENTIONS FOR STROKE
PREVENTION: LESSONS LEARNED
Carotid-artery reconstructive surgery for aneurysms and inva-
sive local cancers was carried out as early as 1916 with resection
and end-to-end anastomosis (2). By 1952, anastomotic techniques
were well-described when substantial portions of the common
and internal carotid arteries had to be sacrificed in the presence of
local cancer. At this time, there was recognition of the importance
of collateral circulation in conjunction with these types of anas-
tomotic surgeries, as well as the importance of autogenous vein
grafting (2). Whereas thrombosis of the common carotid artery
had been described as early as 1881 and predilection for atheroscle-
rosis at the carotid bifurcation and carotid siphon described in the
1900s, C. Miller Fisher’s report in 1951 has been considered the
landmark article on this field (2). In this paper, a neuropatho-
logical correlation was emphasized. He argued for two stroke
mechanisms: decreased flow by high-grade stenosis and embolic
debris migrating downstream causing ischemic stroke. He also
recognized the importance of collateral circulation in relation to
permanency or occurrence of stroke symptoms and prophesized
that surgical intervention might be possible (3).
Thromboendarterectomy was popularized in French literature
in the 1940s (2), which consisted of resection of the intima and
diseased media with the thrombus. However, it was not until the
1990s that carotid endarterectomy (CEA) was proven superior to
medical management alone following several decades of surgical
technique and instrumental refinements that also included a few
failed trials that taught us how to improve our techniques and
refine patient selection criteria (4, 5).
CAROTID BIFURCATION ANGIOPLASTY AND STENTING
Endovascular therapy for the cervical carotid-artery bifurcation
with balloon angioplasty was reported in 1980 (6, 7) and it was
shown to be safe and efficacious (8). Early experiences with bal-
loon angioplasty, however, were complicated by the generation of
embolic debris. Stenting was developed in response to the need for
better outcomes after angioplasty and was proven to be effective by
reducing the occurrence of plaque dislodgement, intimal dissec-
tion, elastic recoil of the vessel wall, and early and late stenosis (7).
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The introduction of a protection device to catch the debris
released during stenting, the basket, theoretically made the
procedure safer and helped launch multiple studies comparing
carotid-artery stenting (CAS) to CEA. Until recently, multiple tri-
als comparing the efficacy and safety of endovascular stenting
for carotid-artery bifurcation to CEA have been carried out with
mixed results. The Carotid Revascularization Endarterectomy vs.
Stenting Trial (CREST) demonstrated similar efficacy and safety
outcomes between the two methods,but only after device improve-
ment and refinement of patient selection (8–10). We suspect that
the history of IER and stenting will experience similar challenges
along the way until we establish the correct device, technique, and
patient selection criteria.
SAMMPRIS METHODS AND STUDY DESIGN
Stenting and Aggressive Medical Management for Preventing
Recurrent Stroke is a Phase III, investigator-initiated, multicen-
ter, randomized, open label, stroke prevention trial funded by
National Institute of Neurological Disorders and Stroke (NINDS)
to determine whether the WS System angioplasty and stenting
arm (WS+ arm) and intensive medical therapy are superior to
intensive medical therapy alone (AMT arm) for preventing stroke
in recently symptomatic patients with severe intracranial athero-
sclerotic stenosis. The trial was initiated in October 2008 and was
conducted at 50 sites in the United States. The details of the study
protocol have been described elsewhere (11).
Patients were randomized if they had TIA or non-disabling
stroke within 30 days prior to enrollment attributed to 70–99%
stenosis of a major intracranial artery. Randomization was at a 1:1
ratio to intensive medical therapy alone or to the WS+ arm.
PRIMARY END POINT
The primary endpoint of the trial was stroke or death within
30 days following enrollment or after a revascularization proce-
dure for the qualifying event during the follow-up period, or stroke
in the territory of the qualifying event beyond 30 days.
ENDOVASCULAR INTERVENTION
The Gateway angioplasty balloon (Boston Scientific, Fremont, CA,
USA) and Wingspan stent (Boston Scientific, San Leandro, CA,
USA) were the only devices allowed in the WS arm of the SAMM-
PRIS trial. The WS System was the only stent in the SAMMPRIS
trial because it was the only FDA-approved device for use at the
time of study.
INTENSIVE MEDICAL THERAPY
Intensive medical therapy in both intervention arms of the study
consisted of aspirin (325 mg/day) for the entire follow-up period,
clopidogrel (75 mg/day for 90 days) after enrollment, and aggres-
sive risk factor management primarily targeting blood pressure to
less than 130/80 mm Hg and low-density lipoprotein-cholesterol
(LDL-C) concentration to <70 mg/dL by administration of anti-
hypertensive agents and rosuvastatin, respectively. A neurologist,
study coordinator, and lifestyle coach closely monitored patients.
Medication compliance was closely monitored by the study coor-
dinator and included pill counts and monitoring of the patients if
they were taking antiplatelet medications, statin therapy, and other
medications.
Patients were examined at enrollment, 30 days, and then every
4 months following enrollment. If blood pressure was not within
target range, adjustments in medical treatment were made and the
patient returned in 30 days for a follow-up visit (1).
STATISTICAL ANALYSIS
Based on the Warfarin–Aspirin Symptomatic Intracranial Disease
(WASID) study, the final projected rate of the primary endpoint
in the medical management group was 24.7% at 2 years taking
into account a 15% relative risk reduction based on the influ-
ence of aggressive medical management. It was then estimated
that 382 patients would be needed in each treatment arm to have
80% power to show a relative reduction of 35% favoring the WS
arm (1).
SAMMPRIS RESULTS
The 30-day rate of stroke and death was 14.7% in the WS arm
(12.5% non-fatal stroke, 2.2% fatal stroke) and 5.8% in the medical
arm (5.3% non-fatal stroke, 0.4% non-stroke death, p= 0.002),
which resulted in the study being stopped prematurely. There
were five stroke-related deaths in the WS arm and one non-
stroke-related death in the medical arm within 30 days following
enrollment. The 30-day rate of primary endpoint in the WS arm
was higher than what the study investigators had anticipated (5.2–
9.6%). Although there was no difference in main outcomes after
30 days of stroke (same territory, 13 patients in each arm), Kaplan–
Meier curves were significantly different with 1-year rates of the
primary endpoint between the WS arm (20.0%) and medical arm
(12.2%, p= 0.009). When the study was stopped, 451 (59%) of the
planned 764 patients had been enrolled; 227 were randomized to
the treatment medical arm, and 224 were randomized to the WS
arm. A futility analysis showed that there was essentially no chance
that the WS arm would be proven superior to medical therapy (1).
Of the 224 patients randomized to the WS arm who underwent
stenting (n= 219) or angioplasty alone (n= 5), 13 had hemor-
rhagic strokes. Seven of the 13 were intraparenchymal bleeds
(IPH), all remote from the stented vessels. A subgroup analysis
of the IPH showed its association with higher degrees of intracra-
nial stenosis, administration of a preoperative clopidogrel loading
dose of 600 mg, and high procedural activated clotting time of
>300 s. Amongst the other hemorrhagic strokes, a total of four
cases were subarachnoid hemorrhages (SAH).
DISCUSSION
SAMMPRIS AMT ARM AND PRIOR MEDICAL LITERATURE
Warfarin–Aspirin Symptomatic Intracranial Disease (WASID)
demonstrated that subsequent stroke risk in patients with sICAD
was related to the degree of vascular stenosis and the clinical pre-
sentation. A subsequent stroke risk in those patients was much
higher than previously reported in other trials. In the WASID
population, patients with >70% stenosis and TIA had a stroke
rate in the first year equal to 14%, and 22.5% if they presented
with stroke and for patients who presented with TIA or stroke
and >70% stenosis, the combined stroke rate was 18% (12). Sur-
prisingly in the SAMMPRIS AMT arm, the stroke rate was 12.2%
in the first year, much lower than the results reported in WASID.
Therefore, based on the above information, there are two possible
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explanations for the discrepancy with the WASID results. Either
the WASID data exaggerated the true risk of symptomatic ICAD
and SAMMPRIS results came to highlight this fact, or the WASID
data were not generalizable to the SAMMPRIS patients.
In SAMMPRIS, however, AMT was applied to both the WS+
and AMT arms. Therefore, if aggressive medical therapy were to
explain the difference between the results in the two treatment
arms (WS+ arm vs. AMT arm), the effect of medication would
have to differ between these two groups, favoring the AMT arm.
We do not have a complete understanding of the profile and
effect of medical risk factor control in the two treatment arms
as long-term follow-up of study patients is currently underway.
For there to be a differential effect in one treatment arm, control
of key risks (e.g., glycosylated hemoglobin, hypertension, lipids,
and physical exercise) would have to differ between the two arms
thereby placing the WS+ arm at a disadvantage. Thus far, we
have seen baseline and 4-month data in relation to key medical
factors and the following observations have been made in the
medical arm vs. WS+ arm at 4 months: systolic/diastolic blood
pressure (134.8/77.3 vs. 133.1/76.2 mm Hg); LDL cholesterol (72.8
vs. 75.9 mg/dL); HDL cholesterol (41.9 vs. 43.2 mg/dL); non-HDL
cholesterol (90.0 vs. 94.3 mg/dL); glycosylated hemoglobin (7.5
vs. 7.8%); current smoking (20.4 vs. 17.3%); moderate or vigor-
ous exercise (56.6 vs. 56.1%). Thus, some of these factors slightly
favor one treatment arm. Additional analyses and follow-up time
will be required to determine the possible influence that these fac-
tors may have on the study outcomes. We are skeptical that these
modest risk factor control differences between the intervention
arms will have major influence on the primary study outcome.
One may consider the effect of combination therapy with
aspirin plus clopidogrel on the results of SAMMPRIS. Since com-
bination antiplatelet therapy was administered to patients in both
treatment groups for the same period of time in this trial, the
expected effect should be constant in both groups unless there
was a differential negative effect, for example, in the WS+ arm,
which does not seem to be the case. Several other aspects of com-
bination antiplatelet therapy are of interest for further discussion.
First, such combination therapy benefited smokers but not non-
smokers in a non-primary analysis of the SAMMPRIS data. This
may be an effect of more efficient conversion of the pro-drug
clopidogrel to its active form by the 450 cytochrome system and
has been observed in other studies (9, 13). Second, the rate of
recurrent stroke in SAMMPRIS was about one-half that of the
precursor study, WASID, which compared high-dose aspirin vs.
warfarin (12.2 vs. 25%) (1, 14). However, if we exclude the periop-
erative strokes in SAMMPRIS then the rate of subsequent ischemic
strokes in the territory of the qualifying artery was almost the
same in the WS+ and medical arms. The 30-day rate of stroke
or death in the angioplasty and stenting group was 14.7%, which
is substantially higher than the rates previously reported ranging
4.4–9.6% (1). Therefore, we conclude that the SAMMPRIS med-
ical regimen may be more advantageous than the WASID medical
treatment regimen, and more careful control of vascular risk fac-
tors in SAMMPRIS was associated with lower risk of subsequent
stroke (1, 14).
On the other hand, before the publication of the WASID study,
the stroke rate in patients with intracranial atherosclerotic disease
was on the order of 10–12% per year in multiple other studies
(15, 16). Contrary to this data, WASID reported a much higher
stroke rate (18%) per year for the patients with 70–99% stenosis
(17). Although we do not know the precise degree of stenosis in
the prior study, it is curious that the medical arm in SAMMPRIS
found the same 12.2% rate of stroke, and we doubt the major-
ity of cases in the prior study had <70% stenosis. As previously
discussed, we wonder whether the WASID results were not gener-
alizable to the SAMMPRIS study patients and thus, overestimated
the real risk of subsequent stroke per year in patients with symp-
tomatic ICAD in SAMMPRIS. However, one should interpret the
findings with caution since neither the results of WASID nor those
of SAMMPRIS have been reproduced in other studies as of yet.
Therefore, at the present time such comparisons may not be valid,
and their results still need to be validated by subsequent study.
However, we believe that the risk of stroke in the first year in the
vascular territory of symptomatic ICAD is at least 12% with best
available AMT.
COMPLICATIONS RATE OF THE WS STENT PRIOR TO
LAUNCHING SAMMPRIS
At a 14.7% complication rate within the first 30 days, the SAMM-
PRIS WS+ arm procedural complication rate was higher than
anticipated. It was almost 2.5 times higher than that observed
for stenting of symptomatic extracranial carotid-artery stenosis in
CREST (8–10). The actual periprocedural complication rate was
in the range of approximately 5–10 absolute percentage points
higher than anticipated. However, we believe that the literature
prior to the SAMMPRIS trial launch anticipated the actual com-
plication rate. An early paper dealing with the complication rate
of the WS System reported a 6.1% major periprocedural neuro-
logical complication rate (18). The important modifier “major”
needs interpretation as all operators know that major compli-
cations are always less frequent than minor complications, trig-
gering an expectation of an at least a 15% total complication
rate (assuming major complications represent approximately 40%
of all complications). This point was further validated in other
studies (Al-Ali et al., May 2008, International Intracranial stent-
ing conference. Ankara. Turkey), reporting their periprocedural
complication rates at 3.6% major, 10.9% minor (total of 14.5%),
and at 19.5% stroke/TIA rate at 1 year. In August of the same
year, The NIH Multicenter Wingspan, Intracranial Stent, Registry
Study results were reported and despite being retrospective and
self-reported the stroke rate was at 14% at 6 months (19). Thus,
concurrent available data on complication and outcome rates of
stenting were generally higher than projected in SAMMPRIS and
suggest the need for a different set of statistical calculations for the
SAMMPRIS trial to avoid failure of the WS+ arm.
IMPROVING THE DESIGN OF SUBSEQUENT TRIALS
A trial to test the merit of IER for stroke prevention in patients
with symptomatic ICAD was, and is still needed. In this text, we
have previously articulated certain reservations about the SAMM-
PRIS trial design, such as use of the WS system as the sole device
allowed in the trial, despite the high complication rate previously
reported in the literature and highlighted above. In addition, other
reservations about SAMMPRIS include:
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PATIENT SELECTION
There has been debate about whether high enough risk patients
were enrolled in the study. Based on the WASID findings, we
understand that those patients with 70–99% stenosis and TIA
or stroke within 30 days before enrollment had the highest rate
of ischemic stroke in the territory of the symptomatic artery
(14). The WASID risk of TIA or stroke was 22.9% at 1 year and
25.0% at 2 years (14). SAMMPRIS was designed using risk esti-
mates from this subgroup of the WASID trial. We agree that
based on the WASID trial, the aforementioned patient risk pro-
file was a reasonable one for choosing patients for eligibility in
SAMMPRIS (11).
LESION MORPHOLOGY
The “Mori classification” [type A <5 mm in length, concentric
or moderately eccentric, smooth stenosis; type B, 5–10 mm in
length, extremely eccentric, or angulated (>45°), or irregular
stenosis, or total occlusion (<3 months old); type C, >10 mm in
length, extremely angulated (>90°) stenosis, or total occlusion
(>3 months old), or lesion with a number of neovasculatures all
around] was not clearly elucidated in the study design eligibility
criteria, despite the fact that it has been well-documented in the
literature (20). It has been shown that lesion length and morphol-
ogy correlate with outcome following IER (20–22). For example,
the intrastent multicenter registry showed much lower rates of
neurological complications in patients with lesions <5 vs. 5- to
10-mm lesions or >10 mm lesions (23). Zhu et al. found a 12%
rate of in-stent restenosis in Mori A lesions and a 50% rate in Mori
C lesions (24). Another recent multicenter report of 670 treated
lesions showed Mori A lesions were safer to treat and were less likely
to develop restenosis (25). The lesions treated in the SAMMPRIS
trial were either 14 mm in length or less (11, 26) but there was no
stratification of the lesions along Mori or other system criteria to
select for favorable lesions to treat.
FRAGILE PLAQUE AND COLLATERAL CIRCULATION STATUS
The presence of numerous micro embolic signals (MES) on
Doppler ultrasound was found to predict a higher risk of sub-
sequent stroke (27). Also, the WASID study revealed that patients
with poor collateral circulation distal to the stenosis had higher
risk of subsequent stroke. The SAMMPRIS trial did not include
criteria taking into account MES or collateral circulation status.
The impact of these factors on such a trial is not clear but needs
to be further defined.
TECHNIQUE
Proper angioplasty technique“slow submaximal balloon inflation”
was described in the late 1990s (28). The authors reported their
experience and noticed that when they started using a smaller bal-
loon 0.5 mm less than the diameter on the diseased vessel at its
normal section and inflating it slowly over a period of 3–5 min to
achieve nominal pressure, their complication rate dropped dra-
matically. The authors attributed this lower complication rate to
decrease in frequency of large dissections at the angioplasty site.
The findings were later confirmed in a major case series demon-
strating that large dissection following angioplasty was associated
with a statistically significant occurrence of stroke in the peripro-
cedural period, and restenosis at follow-up (29). In SAMMPRIS,
operators were encouraged to down size the balloon angioplasty by
0.5 mm, but this was not a requirement, nor was the slow inflation
axiom. Since these data are not documented and not every patient
had an angiography study following angioplasty and prior to stent
placement, it is impossible to know with certainty the impact of
the technique on the final trial results.
LESSONS LEARNED FROM SAMMPRIS TRIAL
We discuss below further insights from and since the publication of
SAMMPRIS in relation to possible means to heighten the success
of IER:
VESSEL SIZE
Stenting and Aggressive Medical Management for Preventing
Recurrent Stroke included vessels that were 2–4.5 mm in diameter.
Vessel diameter was not a predictor of outcome.
VESSELS WITH PERFORATORS VS. VESSELS WITH NO PERFORATORS
Stenting and Aggressive Medical Management for Preventing
Recurrent Stroke demonstrated a higher risk of ischemic stroke
during intervention in vessels with perforators (PV) than in those
with no perforating vessels (nPV). For example, IER to the basi-
lar artery had a higher complication rate than any other vessel.
The importance of this distinction between PV vs. nPV has been
confirmed and in direct comparison of outcomes following IER,
it was found that different vessels carry a very different risk fol-
lowing IER. Vessels with perforators carried significantly higher
risk following IER (MCA 16.3%, basilar artery 20.3%) than when
there were nPV (vertebral artery 8.3%, internal carotid artery
4.9%) (29). Future trials should take this important information
into consideration, by either avoiding PV until newer generation
devices emerge, or by restricting intervention in some patients to
balloon angioplasty using a significantly smaller diameter balloon
and a shorter one.
ROLE OF OPERATOR AND SITE EXPERIENCE
It is important to determine if the higher than expected rate of
endovascular complications in the SAMMPRIS trial was related to
the operator or site experience. The SAMMPRIS analysis showed
that neurointerventionalists with less Wingspan experience did not
have a higher rate of periprocedural strokes in the trial. Neuroin-
terventionalists with a more than a 10-Wingspan case experience
actually had higher rates of 30-day events than those with less
than a 10-case experience (19.0 vs. 9.9%, p= 0.11). Moreover,
high enrolling study sites in this trial had lower rates of hem-
orrhagic stroke; 9.8% at sites enrolling <12 patients vs. 2.7%
at sites enrolling ≥12 patients (p= 0.04). The exact cause of
this difference is not clear but most likely is related to factors
other than the operators’ expertise, such as poor blood pressure
control after stenting and reperfusion injury (30). Final review
of SAMMPRIS results found no association between the opera-
tors’ exact prior experience and the outcome. Other authors have
looked at the importance of the “learning curve” using the WS
system (29). In their series, they observed that complications did
not cluster at the beginning of their use of the WS system but
rather, occurred along the whole period of their registry expe-
rience. This observation suggests that the notion of “increased
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familiarity with the stent or more selective choice of the operators
would have altered the final results of the SAMMPRIS” is probably
inaccurate.
CHALLENGES OF THE WS STENT
THE WINGSPAN STENT
First, the WS stent most likely contributed to the complication
rate in SAMMPRIS. The WS has numerous shortcomings includ-
ing the need for an exchange length micro-wire that must be kept
in place while exchanging the balloon catheter to the stent deliv-
ery catheter. This invariably causes back and forward motion of
the micro-wire tip and possible vessel perforation. Second, the
pusher used to stabilize and help deploy the stent that was very
rigid and invariably causes tension and motion on the wire tip
causing it sometimes to abruptly jump. Third, the stent deliv-
ery catheter is bulky (3.5 French) and advancing such a bulky
catheter through the fresh angioplasty site would, at least the-
oretically, cause further injury to the blood vessel wall. Thus, a
smaller delivery catheter is needed. Lastly, the opposition of the
stent at the angioplasty site is suboptimal due to its lower WS
stent radial force as compared to the balloon-mounted stent. This
suboptimal stent opposition to the vessel wall can allow the per-
sistence of tiny spaces between the stent strut and the vessel wall
allowing for platelet aggregation. This may help explain the curi-
ous phenomenon seen with the use of WS stent, which is the
occurrence of small strokes, days following the intervention. It
is not always in the immediate aftermath of stent placement as
it is customary when using the balloon angioplasty catheter or
the balloon-mounted stent where delayed stroke almost always
equates to stent thrombosis.
CONSIDERATIONS FOR FUTURE TRIALS
From the aforementioned information, we believe that we should
now be able to improve the design of future IER trials based
on better imaging techniques, patient and lesion selection, and
improved procedural techniques. We make the following summary
recommendations:
IMAGING
Digital conventional angiography
Degree of stenosis. Over the last several years, many reports have
demonstrated that lesions more than 70% stenosis have higher
risk of future stroke or TIA. Therefore, we can restrict our lesion
selection to above 70% stenosis.
Lesion morphology. It has been shown repeatedly that Mori C
lesions have a very high complication rate; hence, we believe these
lesions should be excluded from intervention. Numerous reports
have confirmed that lesions in the perforator vessels such as in the
basilar or middle cerebral arteries have much higher complication
rates than those in non-perforator vessels, and it could be that
lesions in the perforator artery presenting with perforant territory
stroke are riskier than those presenting in the perforator artery
with distant stroke (31, 32). This point needs to be clarified before
embarking on a new trial, as we mentioned above. We recommend
a change in the device selection by restricting intervention in these
lesions to angioplasty using balloon with smaller diameter and
shorter length.
Magnetic resonance imaging
Magnetic resonance perfusion imaging is capable of demon-
strating the patient with a focal area of relatively lower perfu-
sion, indicating less robust collaterals. In the WASID study, these
patients were shown to have a higher likelihood of subsequent
stroke. Any future trial should consider including equal numbers
of these patients in both treatment arms to decrease their
potential-cofounding effects.
Doppler ultrasound
Since increase in number of MES correlates with increased chances
of further stroke, taking this finding into account may help refine
the selection of patients and lesions.
TECHNICAL FACTORS
Stenting and Aggressive Medical Management for Preventing
Recurrent Stroke demonstrated that most of the complications
were periprocedural ones. Hence, working hard to decrease these
complications should impact any future trials in a positive way. We
believe the following points are valid based on personal experience
and review of the literature:
Guiding catheter positioning
It should be as close to the lesion as safely possible; intracranial
internal carotid artery, or at C1/C2 level for the vertebral artery.
Our rule of thumb “never more than four curves between the tip
of the guiding catheter and the lesion.” This will decrease the jerky
movement of the micro-wire tip during crossing the lesion and
during any exchange of the micro-catheter system if it becomes
needed. We believe that this requirement is so important that fail-
ure to place the guiding catheter in an acceptable position should
be considered an exclusion criterion.
Angioplasty
Intracranial angioplasty can be performed relatively safely in most
of the patients with intracranial stenosis. It appears that angio-
plasty has a much lower complication rate than any available stent
on the market today. We believe that angioplasty should be the
first line of intervention. Should it be attempted, we believe it
should follow the axiom of submaximal, slow inflation technique.
Currently available stents should be used only as a bail out for
large dissection or significant recoiling of the lesion following
angioplasty (29, 33, 34).
IMPROVING THE AVAILABLE STENT DESIGNS
Safer, more sophisticated stents are needed to improve outcomes
of stenting procedures.
FUTURE DIRECTIONS
The Wingspan self-expanding device used in the SAMMPRIS trial
has potential technical drawbacks, and trials with newer stents
and an angioplasty only arm are warranted. Overtime, more effec-
tive and safer endovascular procedures may be developed and
further trials will be needed to determine if these procedures
with advanced technology lower the risk of stroke compared with
aggressive medical therapy in high-risk subgroups. Until the next
stent generation emerges, angioplasty alone might be an option
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in some of the patients with intracranial stenosis and recurrent
stroke after failure of best medical therapy. Moreover, several sub-
groups of patients with intracranial stenosis are at high risk of
recurrent TIAs and strokes in spite of being on a best medical
therapy such as those with posterior circulation involvement and
high-grade stenosis, and others with recurrent ischemic events
especially with blood pressure fluctuations (35). These patients
may need neurointerventional procedures during the course of
their intracranial stenosis management in spite of being on a best
medical therapy due to recurrent ischemic events. Therefore, it
is important to identify subgroups of patients who are at high
risk of stroke despite being on an aggressive medical therapy pro-
tocol. However, it can be challenging as any neurointerventional
procedure that aims to improve this outcome must have a low
periprocedural complication rate and be able to lower the stroke
rate over time when compared with the best medical therapy. The
SAMMPRIS trial results encourage further research to investigate
and find innovative ways of using endovascular therapies to treat
severe symptomatic intracranial stenosis patients.
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